Yang, Shilun et al. published their research in RSC Advances in 2022 |CAS: 118-55-8

The Article related to cobimetinib antimetabolic agent fabp4 drug target metabolic disease, Placeholder for records without volume info and other aspects.Recommanded Product: Phenyl Salicylate

Yang, Shilun; Li, Simeng; Chang, Junlei published an article in 2022, the title of the article was Discovery of Cobimetinib as a novel A-FABP inhibitor using machine learning and molecular docking-based virtual screening.Recommanded Product: Phenyl Salicylate And the article contains the following content:

Adipocyte fatty acid-binding protein (A-FABP, also called FABP4, aP2) is an adipokine identified as a critical regulator of metabolic function due to its dual functions of fatty acid transport and pro-inflammation. Because of the high therapeutic potential of A-FABP inhibition for the treatment of metabolic diseases and related vascular complications, numerous inhibitors have been developed against A-FABP. However, none of these inhibitors have been approved for use in patients due to severe side effects. Here, we used a virtual screening (VS) strategy to identify potential inhibitors of A-FABP in the latest FDA-approved drug library (∼2600 compounds), aiming to explore the existing drugs with proven safety profiles. We firstly combined ligand-based machine learning and structure-based mol. docking to develop a screening pipeline for identifying A-FABP inhibitors. The screening of FDA-approved drugs identified four compounds (Cobimetinib, Larotrectinib, Pantoprazole, and Vildagliptin) with the highest scores, whose inhibitory effects on A-FABP were further assessed in cellular assays. Among the selected compounds, Cobimetinib significantly inhibited the activation of the JNK/c-Jun signaling pathway by A-FABP in mouse macrophages without causing obvious cytotoxicity. In summary, we present an integrated VS pipeline for A-FABP inhibitor screening, and identified Cobimetinib as a novel A-FABP inhibitor that may be repurposed for the treatment of metabolic diseases and associated vascular complications. The experimental process involved the reaction of Phenyl Salicylate(cas: 118-55-8).Recommanded Product: Phenyl Salicylate

The Article related to cobimetinib antimetabolic agent fabp4 drug target metabolic disease, Placeholder for records without volume info and other aspects.Recommanded Product: Phenyl Salicylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics